[{"orgOrder":0,"company":"Stella Pharma","sponsor":"TAE Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"P-Borono-L-Phenylalanine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Stella Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Stella Pharma \/ TAE Life Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Stella Pharma \/ TAE Life Sciences"}]

Find Clinical Drug Pipeline Developments & Deals by Stella Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Generic Rx Session
                          Not Confirmed
                          The Generic Rx Session
                          Not Confirmed

                          Details : The collaboration aims to focus on the development, commercialization and expansion of boron neutron capture therapy using Steboronine (boronophenylalanine) in the United States and European markets.

                          Product Name : Steboronine

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 13, 2024

                          Lead Product(s) : P-Borono-L-Phenylalanine

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : TAE Life Sciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank